Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Schizophrenia or Schizoaffective Disorder
NCT06878833Phase 3Withdrawn
- Sponsor
- Lyndra Therapeutics
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial of LYN-005 in schizophrenia and schizoaffective disorder (3 arms), sponsored by Lyndra Therapeutics. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at Day 203. Planned start Apr 2025; status: withdrawn.
02
Drugs
LYN-005
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT06878833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878833.